# Eton Pharmaceuticals Secures U.S. Rights for LIBERVANT in $10M Deal

- URL: https://stocks.freetheai.org/news/eton-pharmaceuticals-secures-u-s-rights-for-libervant-in-10m-deal-343ebc
- Published: 2026-10-14T11:23:00Z
- Category: company_news; sentiment: bullish; impact: medium
- Symbols: [NASDAQ:ETON](https://stocks.freetheai.org/symbols/NASDAQ-ETON)
- Written by our AI from expert market sources across the web for FreeTheAI Stocks, built by Vibhek Soni
- How write-ups are made: https://stocks.freetheai.org/how-we-write
- Not financial advice: https://stocks.freetheai.org/disclaimer

Eton Pharmaceuticals (ETON) has acquired exclusive U.S. commercialization rights to LIBERVANT (diazepam) buccal film from Aquestive Therapeutics. Under the licensing agreement, Eton paid $10 million upfront and could pay up to $47.5 million in additional milestone payments, alongside mid-teens royalties on net product sales.

The transaction gives Eton exclusive commercial access to a potential new epilepsy rescue therapy in the United States, where LIBERVANT currently holds tentative FDA approval for select age groups. In tandem with the license, Eton signed a 20-year exclusive supply agreement designating Aquestive as LIBERVANT's U.S. manufacturer.

Looking ahead, commercial expansion will depend on obtaining final FDA regulatory approvals required for full market launch, after which Eton will begin U.S. commercialization efforts.

## Key points

- Eton Pharmaceuticals paid $10 million upfront for exclusive U.S. commercial rights to LIBERVANT.
- Eton agreed to pay up to $47.5 million in milestone payments plus mid-teens royalties on net sales.
- A separate 20-year exclusive agreement designates Aquestive Therapeutics as the U.S. manufacturer.
- Full U.S. commercial launch remains subject to receiving final FDA approvals.

## Questions and answers

### What did Eton Pharmaceuticals acquire from Aquestive Therapeutics?

Eton acquired exclusive U.S. commercialization rights to LIBERVANT (diazepam) buccal film to target the epilepsy market.

### How much did Eton Pharmaceuticals pay for the LIBERVANT licensing deal?

Eton paid $10 million upfront, with up to $47.5 million in potential milestone payments and mid-teens royalties on net sales.

### Who will manufacture LIBERVANT for Eton Pharmaceuticals in the U.S.?

Aquestive Therapeutics will serve as the exclusive U.S. manufacturer under a 20-year supply agreement.